Document Detail

Ablative fractional resurfacing for involuted hemangioma residuum.
MedLine Citation:
PMID:  22910902     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND Given the natural tendency for 15% to 40% of infantile hemangiomas to spontaneously involute over time, much debate surrounds the issue of treatment. Until recently, effective therapies to improve the appearance of residual textural skin changes in these patients were lacking. We suggest the use of ablative fractional resurfacing for the treatment of textural skin changes resulting from involuted hemangiomas. OBSERVATIONS All patients treated with an ablative fractional carbon dioxide laser experienced considerable flattening of the fibrofatty residual tissue, with at least 50% to 75% improvement in color, texture, and overall appearance. CONCLUSION While additional future studies are needed, we believe that ablative fractional resurfacing should be considered for the treatment of textural skin changes associated with involuted infantile hemangiomas.
Lori A Brightman; Jeremy A Brauer; Vitaly Terushkin; Christopher Hunzeker; Kavitha K Reddy; Elliot T Weiss; Julie K Karen; Elizabeth K Hale; Robert Anolik; Leonard Bernstein; Roy G Geronemus
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of dermatology     Volume:  148     ISSN:  1538-3652     ISO Abbreviation:  Arch Dermatol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-02-12     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1294-8     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Response selection in prosaccades, antisaccades, and other volitional saccades.
Next Document:  Inactivation of pyruvate dehydrogenase kinase 2 by mitochondrial reactive oxygen species.